Immunic (NASDAQ:IMUX) Upgraded by Lifesci Capital to “Strong-Buy” Rating

Immunic (NASDAQ:IMUX) was upgraded by Lifesci Capital to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Several other equities research analysts have also weighed in on the company. Guggenheim initiated coverage on Immunic in a report on Tuesday, March 24th. They issued a “buy” rating and a $70.00 target price for the company. upgraded Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. HC Wainwright restated a “buy” rating and issued a $22.00 target price (up from $5.00) on shares of Immunic in a report on Thursday. D. Boral Capital lowered Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. Finally, Wall Street Zen lowered Immunic from a “hold” rating to a “sell” rating in a report on Sunday, April 19th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $52.43.

Immunic Stock Performance

IMUX opened at $10.62 on Monday. The business has a 50 day moving average price of $11.07 and a 200 day moving average price of $8.40. Immunic has a twelve month low of $5.06 and a twelve month high of $15.10. The firm has a market cap of $144.64 million, a P/E ratio of -1.52 and a beta of 1.20.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, February 26th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.18). As a group, analysts anticipate that Immunic will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nantahala Capital Management LLC bought a new stake in Immunic in the 4th quarter valued at $2,337,000. Millennium Management LLC increased its holdings in Immunic by 544.6% in the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after buying an additional 2,888,829 shares during the period. Laurion Capital Management LP increased its holdings in Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after buying an additional 2,000,000 shares during the period. Marshall Wace LLP increased its holdings in Immunic by 91.2% in the 4th quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock valued at $541,000 after buying an additional 486,468 shares during the period. Finally, Simplify Asset Management Inc. bought a new stake in Immunic in the 1st quarter valued at $487,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.